Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.39 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17709408 | 0.92 | ACHE (0.39) | ACHEHRH3HSD17B10 | |
| SCHEMBL16942329 | 0.89 | ACHE (0.44) | ACHECYP2B6TENT4ATENT4BTSHR | |
| SCHEMBL16942330 | 0.89 | ACHE (0.44) | ACHECYP2B6TENT4ATENT4BTSHR | |
| SCHEMBL16929820 | 0.89 | ACHE (0.44) | ACHECYP2B6TENT4ATENT4BTSHR | |
| SCHEMBL17709330 | 0.88 | ACHE (0.43) | ACHECYP2B6TENT4ATENT4BTSHR | |
| SCHEMBL17709317 | 0.87 | ACHE (0.43) | ACHECYP2B6TENT4ATENT4BTSHR | |
| SCHEMBL17709305 | 0.87 | ACHE (0.38) | ACHECYP2B6TENT4ATENT4BHSD17B10 | |
| SCHEMBL16942345 | 0.85 | CYP2B6 (0.43) | ACHECYP2B6TENT4ATENT4B | |
| SCHEMBL16929874 | 0.85 | CYP2B6 (0.43) | ACHECYP2B6TENT4ATENT4B | |
| SCHEMBL16942343 | 0.85 | CYP2B6 (0.43) | ACHECYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | claimed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | claimed |
| EP-3215504-B1 | 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-3215504-B1 | 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637485-B2 | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122344-A1 | Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, SLC10A1, CYP2D6 | ACHE 2643/4885CYP2B6 5/4885TENT4A 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.